TIGIT and familial pancreatic carcinoma: Therefore, to combat an immunosuppressive pancreatic cancer TME, we hypothesize that a combinatorial strategy comprising (1) neoantigen vaccination to generate neoantigen-specific immune responses, and (2) immune checkpoint blockade of TIGIT/PD-1, is worth pursuing.